BioSpace News Archive

Rexgenero, a regenerative medicine company pioneering the development of advanced cell-based therapies to treat chronic limb-threatening ischaemia, welcomes the news announced by Atelerix that it has been awarded a grant of £267,000 from Innovate UK.

Fusion Antibodies plc, specialists in pre-clinical antibody discovery, engineering and supply for both therapeutic drug and diagnostic applications, confirms that the Annual Report and Accounts for the year ended 31 March 2019, the Notice of Annual General Meeting and a Form of Proxy will be posted to shareholders later.

Polyphor AG announced that it will host a Key Opinion Leader (KOL) breakfast meeting on novel approaches to the treatment of metastatic breast cancer on Friday, September 6, 2019 in New York City.

Oxford Immunotec Global PLC announced that Dr. Peter Wrighton-Smith, Chief Executive Officer, and Matt McLaughlin, Chief Financial Officer, will be participating in two upcoming investor conferences.

Singapore molecular diagnostics groups INEX Innovations Exchange Pte. Ltd. (INEX) and Nova Satra Dx Pte. Ltd. (Nova Satra) announced the merger of the two companies to create INEX INNOVATE.

In mice whose lungs were damaged, the research team took specialized lung cells called alveolar type-two cells from healthy mice and allowed the sick animals to breathe in the cells.

NuCana halted enrollment of patients in the Phase III ACELERATE trial on the advice of the study’s Independent Safety and Data Monitoring Committee.

Merck’s checkpoint inhibitor Keytruda (pembrolizumab) has been approved for 21 indications, but you’d better keep up, because it seems the drug is approved for some new indication or combination just about every week.

Although a definite blow to Sarepta, this may have negative implications for other companies working to develop therapies for DMD. This includes Wave Life Sciences and Solid Biosciences.

Hansa Biopharma has been invited to participate in three global biotech and healthcare conferences during September including Goldman Sachs’ Biotech Symposium in London, Morgan Stanley’s Global Healthcare conference in New York City and Bank of America Merrill Lynch Global Healthcare Conference in London